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TURKISH PHYSICIAN PRESCRIPTION PATTERNS 
FOR HYPERTENSION MANAGEMENT
Sapci H1, Bozkurt E2, Durlu T2, Kandilci B2, Ozsogut B2, 
Demirdamar R2
1Numune Hospital, Ankara, Turkey; 2Faculty of Pharmacy, 
Hacettepe University, Ankara, Turkey
OBJECTIVE: In our country rational drug prescription
and use has not been established yet. Moreover, because
there is a lack of pharmacoeconomic research, it is hard
to point the real state of art. Use of information technolo-
gies in the control of rational prescription habits is nil.
We analyzed hypertensive patient prescriptions to evalu-
ate existing practice habits. From the prescription habit
profiles thus obtained and taking into consideration the
recent reports of JNC-VI and WHO recommendations
that are currently used in our country in medical educa-
tion, we aimed to propose an urgent need for guidelines
and hospital formularies. METHODS: 1864 prescrip-
tions were obtained from the social security systems and
the relevant data of 253 patients diagnosed as hyperten-
sion was entered to SPSS. RESULTS: The analysis of the
prescriptions revealed inappropriate initial drug therapy
in hypertension (43%). In these cases initial drug therapy
for isolated hypertension began with ACE inhibitors. Av-
erage ACE inhibitor costs $12.32 and taking Turkey’s
economic situation, they are not cost-effective. Most striking
characteristic of analyzed prescriptions was polypharmacy
(5 or 4 drugs  61%). Furthermore we observed unnec-
essary drug class switch (less then 10 days) in 36 pre-
scriptions. CONCLUSIONS: The results of our analysis
has led us to the following conclusions. Drug choice for
initial drug therapy and drug class switch is not in accor-
dance with international guidelines. Unethical promotion
(a widespread problem in Turkey) probably being the
major cause. Polypharmacy, a problem we have been try-
ing to solve since the last 15 years, still exists. By prepa-
ration and effective use of therapeutic guidelines and hos-
pital formularies both polypharmacy and irrational drug
prescription can be solved.
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ANNUAL COST OF TREATING HYPERLIPIDEMIA 
IN A MANAGED CARE POPULATION
Shahriar J1, McLaughlin T2, Margraf T3
1The University of Arizona, Tucson, AZ, USA; 2NDC Health 
Information Services, Phoenix, AZ, USA; 3PharMetrics, Inc., 
Boston, MA, USA
OBJECTIVE: To characterize the treatment, and associ-
ated costs, of hyperlipidemia in a managed care population.
METHODS: All patients within PharMetric’s Integrated
Outcomes Database possessing a diagnosis of hyperlipi-
demia (ICD-9-CM  272.0, 272.1, 272.2, 272.4) during
1997 were eligible for study inclusion. Patients with less
than 12 months of enrollment prior to or following the
initial diagnosis, or a prescription claim for a lipid-lower-
ing agent or medical claim for a cardio/cerebrovascular
event (CVE) prior to diagnosis, were excluded from the
analysis. Patient demographics, hyperlipidemia-specific
charges, prescription claims for lipid lowering agents,
and comorbid conditions were captured for each patient
during the study period. RESULTS: 16,187 patients met
the inclusion criteria. The mean age was 51.7 years (SD 
11.5), and 59.1% were female. The most common
comorbidities were hypertension (35.3%) and diabetes
(12.5%). Only 21% of patients had a prescription claim
for a lipid-lowering agent within 12 months of diagnosis.
The most common agents were the HMG-COA reduc-
tase inhibitors, prescribed to 3030 patients (18.7%). 239
patients (1.5%) had a CVE within 12 months of diagno-
sis—the most common of which was atherosclerosis
(28.9%) followed by acute myocardial infarction (4.2%).
The incidence of CVEs was positively correlated with
age, ranging from 0.8% in patients 55 to 6.52% in pa-
tients 80 years of age. The mean hyperlipidemia-spe-
cific charges per patient were $3,047 (SD  7168) for the
year prior and $5,260 (SD  13470) for the year follow-
ing the index diagnosis. For patients having a CVE, the
mean total charges were $44,213 (SD  39787). CON-
CLUSION: Hyperlipidemia represents a substantial cost
burden to health systems. Pharmaceutical treatment, de-
spite evidence of its effectiveness, was relatively uncom-
mon in this population.
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VARIATION IN MEDICAL RESOURCE 
UTILIZATION IN THE MANAGEMENT OF 
PULMONARY EMBOLISM
Annemans L1, Robays H2
1HEDM, Meise, Belgium, 2University Hospital, Ghent, Belgium
OBJECTIVES: Databases provide aggregated and con-
founded data regarding management and cost of pulmo-
nary embolism (PE). The objective of this study was to
investigate, via patient chart analysis, the average and the
variation in medical resource use strictly related to PE pa-
tients, and to find explanatory factors for the possible
variation. METHODS: Patients with confirmed PE (n 
54) were randomly selected from 5 Belgian centres. The
centres were representative for size and region. The
charts were analyzed in detail, based on a standardized
case record form. Only medical resource use related to
the treatment of presumed and confirmed PE was in-
cluded in the analysis, with a time horizon from the day
of suspicion up to discharge. RESULTS: On average, the
management of PE is rather consistent across centres.
The total average cost of PE was equal to 3,394 Euro
(95% CI  2,762–4,027 Euro). Still, large inter-individ-
ual differences are found in the intensity of diagnosis and
follow-up. More in particular, a large variation in hospi-
tal duration is found, (average  14.6 days, Std. Dev. 
9.3), but this effect was not explained by the type of cen-
tre nor the region. The only two factors that are signifi-
cantly related with hospital duration in a multivariate re-
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gression analysis are the number of days of heparin use
and the intensity of diagnostic follow-up, as expressed by
the number of VQ-scans. CONCLUSIONS: The manage-
ment of PE, from suspicion until discharge, is rather con-
sistent; however, large inter-individual variation in hospital
stay is observed. Interestingly, the length of hospitaliza-
tion is related to the duration of heparin use. This perhaps
opens perspectives for anticoagulation that can be ad-
ministered ambulatory. A patient chart review has the
advantage over database research that only resource use
strictly related to the investigated condition can be identified.
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COST-EFFECTIVENESS OF HMG-CoA 
REDUCTASE INHIBITORS AND FIBRATES 
THERAPY IN ELDERLY WOMEN WITH 
CORONARY ARTERY DISEASE
Lazebnik LB, Kadiskaya MJ
Russian Medical Academy for Postgraduate Education, 
Moscow, Russia
OBJECTIVE: To determine pharmacoeconomically opti-
mal hypolipidemic drug for preventive maintenance of
CAD in women of elder age groups. METHODS: 110
women, average age 59  3,4 yrs., with menopause du-
ration more than 5 years, hypercholesterolemia types IIA
and IIB, coronary heart disease, angina pectoris of II–III
functional class without clinical signs of heart insuffi-
ciency were included into the study. They were divided
into 5 groups by a method of envelopes: patients of I
group received simvastatinin - 10–20 mg o.d., patients of
II group - fluvastatin 40–80 mg o.d., patients of III group -
pravastatin 20–40 mg o.d., IV group - fenofibrate 200
mg o.d., V group-ciprofibrate - 100 mg o.d. Statins were
initially given in bioequivalent doses. The groups of ther-
apy were completely comparable to age; duration of dis-
ease and character of accompanying therapy, and also by
levels TC and LDL-C Therapy duration was 12 weeks.
After 4 and 12 weeks the levels of TC, LDL-C, HDL-C,
TG and also conventional biochemical criterion of safety
of therapy were determined. The criterion of cost-effec-
tiveness for each drug was defined under the following
formula, permitting to determine the cost of 1% reduc-
tion of LDL-C by various hypolipidemic drugs: Ñ-E 
(DMC  FC)/% of LDL-C reduction, where DMC—the
direct medical costs including cost of a medical reception
and cost of an out-patient inspection according to the
standards of the prices for medical services in adult out-
patient departments of Moscow under the program of
voluntary medical insurance in 1997–98; FC-cost of a
monthly course of treatment by different drugs in Mos-
cow chemist’s web in 1997–98. CONCLUSION: The
comparison of hypolipidemic drugs by a criterion “cost-
effectiveness”, using as a criterion of therapy efficiency
percentage of LDL-C reduction, arranged the drugs as
follows: ciprofibrate (100 mg) - fluvastatin (40 mg) - sim-
vastatin (10 mg) - fenofibrate (200mg) - fluvastatin (80mg) -
simvastatin (20mg) - pravastatin (20 mg) - pravastatin
(40 mg).
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VARIATION IN COSTS OF TREATING 
HYPERCHOLESTEROLEMIC PATIENTS
IN FRANCE
Smith D
University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: To examine the variation in total costs of
treating patients with hypercholesterolemia to achieve
EAS LDL-C target concentration levels using statins.
METHODS: A randomized, 54-week, controlled trial
was conducted to compare resources used when treating
patients to EAS LDL-C targets using atorvastatin, fluva-
statin, pravastatin and simvastatin. Variation in total
costs among the arms of the study could be attributed to
the time at which patients achieved LDL-C targets and
the services and medications required to reach LDL-C
target. Costs include costs of study drug, add-on therapy,
physician office visits, lab tests and attributable adverse
events. RESULTS: There was substantial variation in to-
tal costs and in the components of total costs among
study arms. Patients treated with atorvastatin achieved
LDL-C target significantly faster (P  0.05) at lower
doses of study drug and required significantly fewer clinic
visits than patients treated with comparator statins. Con-
sequently, mean total cost of care to reach LDL-C targets
were significantly lower than costs for patients treated
with comparators (P  0.05). CONCLUSION: Costs for
treating patients to LDL-C targets with HMG-CoA re-
ductase inhibitors varied significantly among drugs. To-
tal costs of therapy were lowest with atorvastatin, when
compared to other reductase inhibitors examined in this
study.
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THE COST OF REACHING LDL-C TARGETS IN 
SPAIN: A COMPARISON AMONG STATINS
Smith D
University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: To examine the variation in total costs of
treating patients according to EAS LDL-C target concen-
tration levels attributable to use of alternative HMG-
CoA reductase inhibitors (statins). METHODS: A ran-
domized, 54-week, controlled trial was conducted to
compare resources used when treating patients to EAS
LDL-C targets using atorvastatin, fluvastatin, pravastatin
and simvastatin. The trial enrolled 336 patients. Patients
were dispensed study drugs according to the protocol;
starting at the lowest dose and titrating up at regular in-
tervals if LDL-C targets were not met. Per the protocol,
the amount of resources consumed varied based upon the
time at which patients achieved LDL-C targets. In this
treat-to-target study, it was possible to achieve target in
